Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy

• DOI: 10.1038/s41416-018-0168-9
• Publication Date: 2018-07-03T11:38:51Z
• Authors: Frantz Dupuis; Laurence Lamant; Emilie Gerard; Nouritza Torossian; Leonor Chaltiel; Thomas Filleron; Marie Beylot-Barry; Caroline Dutriaux; Sorilla Prey; Audrey Gros; Marie-Laure Jullie; Nicolas Meyer; Béatrice Vergier
• Keywords: CD163; Targeted Therapy

Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status technically challenging and mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive a response to anti-PD-1 therapy could contribute improving decision-making. This retrospective study on 70 metastatic patients was undertaken evaluate the relationships between clinical, histological, immunohistochemical and/or molecular criteria, 6-month objective rate. Better rates were associated with metachronous metastases (P = 0.04), PD-L1 tumour- immune-cell 0.01), CD163+ histiocytes at advancing edges 0.009) primary melanomas NRAS mutation 0.019). Moreover, 0.04) longer progression-free survival (PFS), overall 0.02) PFS 0.049). Combining these help improve decision-making progressive disease.